ArticleJournal of veterinary pharmacology and therapeutics2016
Subcutaneous meloxicam suspension pharmacokinetics in mice and dose considerations for postoperative analgesia.
Article in Journal of veterinary pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2017Trial
- Pharmacokinetics of Single-dose Subcutaneous Meloxicam Injections in Black-tailed Prairie Dogs (Journal of the American Association for Laboratory Animal Science : JAALAS · 2017Trial
- Mechanical unloading promotes adult cardiomyocyte proliferation through epicardial NRG1-ERBB4 signaling.Nature cardiovascular research · 2026Article
- Surgical hematoma removal promotes skeletal muscle recovery in a rat laceration model.Scientific reports · 2026Article
- Suitability of prolonged meloxicam treatment in mice seems limited due to unfavorable pharmacokinetics, side effects, and impact on home-cage behaviors.Scientific reports · 2025Article
- Effect of Gender on the Pharmacokinetics of Meloxicam in Sheep.Journal of veterinary pharmacology and therapeutics · 2025Article
- Pancreatic Tissue Remodeling and Fibrosis After Irreversible Electroporation: A Histopathological and Thermal Perspective.Biomedicines · 2025Article
- Pharmacokinetic variability of 20(S)-protopanaxadiol-type ginsenosides Rb1, rd, and compound K from Korean red ginseng in experimental rodents.Scientific reports · 2025Article
- Article
- Testing perioperative meloxicam analgesia to enhance welfare while preserving model validity in an inflammation-induced seizure model.Scientific reports · 2024Article
- Pharmacokinetics of Injectable Meloxicam and Buprenorphine in the Naked Mole-Rat (Journal of the American Association for Laboratory Animal Science : JAALAS · 2024Article
- Antinociceptive and Cardiorespiratory Effects of a Single Dose of Dexmedetomidine in Laboratory Mice Subjected to Craniotomy under General Anaesthesia with Isoflurane and Carprofen or Meloxicam.Animals : an open access journal from MDPI · 2024Article
- High-dose Meloxicam Provides Improved Analgesia in Female CD1 Mice: A Pharmacokinetic and Efficacy Study.Journal of the American Association for Laboratory Animal Science : JAALAS · 2023Article
- Injection-site Reactions to Sustained-release Meloxicam in Sprague-Dawley Rats.Journal of the American Association for Laboratory Animal Science : JAALAS · 2020Article
- Concentration-dependent Toxicity after Subcutaneous Administration of Meloxicam to C57BL/6N Mice (Journal of the American Association for Laboratory Animal Science : JAALAS · 2019Article
- Sterility and Stability of Diluted Meloxicam in Compounded Multi-dose Vial after 365 Days.Journal of the American Association for Laboratory Animal Science : JAALAS · 2019Article
- Subcutaneous meloxicam suspension pharmacokinetics in mice and dose considerations for postoperative analgesia.Journal of veterinary pharmacology and therapeutics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meloxicam is a cyclooxygenase (COX) inhibitor with a higher selectivity for cyclooxygenase-2 (COX-2) than for cyclooxygenase-1 (COX-1). In the laboratory setting, this nonsteroidal anti-inflammatory drug (NSAID) is commonly selected for analgesia in mice and administered every 24 h. This study characterizes the plasma concentration achieved from a dose of 1.6 mg/kg of meloxicam administered once every 24 h subcutaneously for 72 h in male and female C57BL/6 mice. These values were compared, over time, to reference COX-2 inhibition constants for meloxicam. No significant differences in trough plasma concentrations were noted between genders. The plasma concentrations were below the COX-2 IC50 after 12 h. To maintain a plasma concentration at or above the COX-2 whole blood IC50, the study results suggest an administration frequency of every 12 h when using a dose of 1.6 mg/kg in C57BL/6 mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.